A phase I dose escalation trial to evaluate safety and efficacy of oral sorafenib (Nexavar) with regional melphalan via normothermic isolated limb infusion (ILI) in patients with intransit extremity melanoma.

Trial Profile

A phase I dose escalation trial to evaluate safety and efficacy of oral sorafenib (Nexavar) with regional melphalan via normothermic isolated limb infusion (ILI) in patients with intransit extremity melanoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Mar 2013

At a glance

  • Drugs Sorafenib (Primary) ; Melphalan
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Dec 2011 Additional lead trial center identified as reported by ClinicalTrials.gov.
    • 18 Apr 2009 Planned number of patients changed from 22 to 28 as reported by ClinicalTrials.gov.
    • 23 Sep 2008 Planned end date changed to 1 Dec 2014, as reported by ClinicalTrials.gov..
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top